The Daily29 Des 2024

The Sunday Read: ‘Ozempic Could Crush the Junk Food Industry. But It Is Fighting Back.’

For decades, Big Food has been marketing products to people who can’t seem to stop eating, and now, suddenly, they can. The active ingredient in new drugs like Ozempic, Wegovy and Zepbound mimics a natural hormone that slows digestion and signals fullness to the brain.

Around seven million Americans take these drugs, but estimates from Morgan Stanley suggest that number could increase to 24 million within the next decade. More than 100 million American adults are obese, and the drugs may eventually be rolled out to people who don’t have diabetes or obesity, as they seem to tame addictions beyond food — appearing to make cocaine, alcohol and cigarettes more resistible. Research is at an early stage, but the drugs may also cut the risk of stroke, heart and kidney disease, Alzheimer’s and Parkinson’s.

Major food companies are scrambling to research the impact of the drugs on their brands — and figure out how to adjust. But for Mattson, which has invented products for the nation’s biggest food conglomerates for nearly 50 years, the Ozempic threat could be a boon.

For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

Subscribe today at nytimes.com/podcasts or on Apple Podcasts, Spotify and Amazon Music. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(2982)

How a 1,000-Year-Old Tapestry Took London by Storm

For the first time in centuries, the Bayeux Tapestry — a nearly 1,000-year-old piece of embroidery that depicts the invasion of England by William the Conqueror in 1066 — is on display in Britain.It w...

20 Sep 34min

Aaron Sorkin Goes Off Script

The Oscar-winning writer returns to Facebook with “The Social Reckoning”— and surprises us with the revelation of why he is so drawn to uplift and romance. Thoughts? Email us at theinterview@nytimes.c...

19 Sep 1h

The Techno-Religion at the Center of the A.I. Debate

Last week, a group of tech leaders called for putting guardrails on artificial intelligence. This week, these calls have been met by backlash from tech executives, lawmakers and President Trump, who l...

18 Sep 34min

Why Gas Prices Just Keep Going Up

About a month into the war with Iran, we spoke with Cameron Joudi, who owns a gas station in Florida, about how the conflict was reaching him at home. He recently reached out after seeing a 20-cent sp...

17 Sep 23min

48 Days Until the Midterms: Is a Blue Wave Coming?

As the general midterm elections begin, we take a look at where things stand. A new Times/Siena poll suggests that Democrats have a real shot at winning control of both chambers of Congress. But serio...

16 Sep 36min

The Bond Market Is Flipping Out. Here’s Why You Should Care.

For the past few months, you’ve probably been hearing about the turbulence in the bond market.Today, Ben Casselman, the chief economics correspondent for The New York Times, explains what has been hap...

15 Sep 28min

The A.I. Researcher Whose Rebellion Is Changing Everything

In recent days, Jacob Coxon, a researcher at the artificial intelligence company Anthropic, quit his job and posted warnings about the risks of the technology. That kicked off a crisis that culminated...

14 Sep 34min

The Good, the Bad and the Good-Bad (Movie)

When it comes to movies we love, there are the artistic masterpieces and there are the foot-stomping crowd pleasers. But there’s another particular kind of beloved movie, the one that makes our friend...

13 Sep 37min